New Medical Applications of Plant Secondary Metabolites

Functions and Biotechnology of Plant Secondary Metabolites: Second Edition

Volumn 39, Issue , 2010, Pages 348-380

  Heilmann, Jörg ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Anti inflammatory; Anticancer; Antidepressant; Antiviral; Artemisinin; Betulinic acid; Boswellic acids; Camptothecins; Chemoprevention; Combretastatin A 4; Curcumin; Ginkgo; Hypericum perforatum; Polyphenols; Taxanes; Xanthohumol

Indexed keywords

BIOMOLECULES; CYTOLOGY; FUNCTIONAL POLYMERS; MEDICAL APPLICATIONS; METABOLITES;

ANTI-INFLAMMATORIES; ANTICANCER; ANTIDEPRESSANT; ANTIVIRAL; ARTEMISININ; BETULINIC ACID; BOSWELLIC ACIDS; CAMPTOTHECINS; CHEMOPREVENTION; COMBRETASTATIN A-4; CURCUMIN; GINKGO; HYPERICUM PERFORATUM; POLYPHENOLS; TAXANES; XANTHOHUMOL;

PLANTS (BOTANY);

EID: 84893461405     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444318876.ch5     Document Type: Chapter

References (221)

1. Abdulla, S., Sagara, I., Borrmann, S., D'Alessandro, U., González, R., Hamel, M., Ogutu, B., M°artensson, A., Lyimo, J., Maiga, H., Sasi, P., Nahum, A., Bassat, Q., Juma, E., Otieno, L., Björkman, A., Beck, H.P., Andriano, K., Cousin, M., Lefèvre, G., Ubben, D. and Premji, Z. (2008) Efficacy and safety of artemether-lumefantrine dispersible tablets compared with crushed commercial tablets in African infants and children with uncomplicated malaria: a randomised, single-blind, multicentre trial. Lancet, 373, 1819-27.
2. Adlercreutz, H. and Mazur, W. (1997) Phyto-oestrogens and Western diseases. Ann. Med., 29, 95-120.
3. Aggarwal, B.B., Kumar, A. and Bharti, A.C. (2003) Anticancer potential of curcumin:preclinical and clinical studies. Anticancer Res., 23, 363-98.
4. Ahlemeyer, B. and Krieglstein, J. (1998) Neuroprotective effects of Ginkgo biloba extract, in Phytomedicines of Europe: Chemistry and Biological Activity (eds. L.D. Lawson and R. Bauer), ACS Symposium Series 691, ACS Books, Washington, pp. 210-20.
5. Ahlemeyer, R. and Krieglstein, J. (2003) Pharmacological studies supporting the therapeutic use of Ginkgo biloba extract for Alzheimer's disease. Pharmacopsychiatry, 36 (Suppl 1), S8-14.
6. Akiyama, T., Ishida, J., Nakagawa, S., Ogawara, H., Watanabe, S., Rob, N., Shibuya, M. and Fukami, Y. (1987) Genistein, a specific inhibitor of tyrosine-specific protein kinases. J. Biol. Chem., 262, 5592-5.
7. Akiyama, T. and Ogawara, H. (1991) Use and specificity of genistein as inhibitor of protein tyrosine kinases. Meth. Enzymol., 201, 362-70.
8. Albini, A., Dell'Eva, R., Vene, R., Ferrari, N., Buhler, D.R., Noonan, D.M. and Fassina, G. (2006) Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol:NF-kappaB and Akt as targets. FASEB J., 20, 527-9.
9. Altmann, K.H., Pfeiffer, B., Arseniyadis, S., Pratt, B.A. and Nicolaou, K.C. (2007) The chemistry and biology of epothilones-the wheel keeps turning. ChemMedChem., 2, 396-423.
10. Ammon, H.P.T., Safayhi, H., Mack, T. and Sabieraj, J. (1993) Mechanism of antiinflammatory actions of curcumine and boswellic acids. J. Ethnopharmacol., 38, 113-9.
11. Anderson, R.F., Fisher, L.J., Hara, Y., Harris, T., Mak, W.B., Melton, L.D. and Packer, J.E. (2001) Green tea catechins partially protect DNA from OH radical-induced strand breaks and base damage through fast chemical repair of DNA radicals. Carcinogenesis, 22, 1189-93.
12. Ansari, J., Hussain, S.A., Zarkar, A., Tanguay, J.S., Bliss, J. and Glaholm, J. (2008) Docetaxel chemotherapy formetastatic hormone refractory prostate cancer as firstline palliative chemotherapy and subsequent re-treatment: birmingham experience. Oncol. Rep., 20, 891-6.
13. Arguello, F., Alexander, M., Sterry, J.A., Tudor, G., Smith, E.M., Kavalar, N.T., Greene, J.F., Jr., Koss, W., Morgan, C.D., Stinson, S.F., Siford, T.J., Alvord, W.G., Klabansky, R.L. and Sausville, A. (1998) Flavopiridol induces apoptosis of normal lymphoid cells, causes immunosuppression and has potent antitumor activity in vivo against human leukemia and lymphoma xenografts. Blood, 91, 2482-90.
14. Argyriou, A.A., Koltzenburg, M., Polychronopoulos, P., Papapetropoulos, S. and Kalofonos, H.P. (2008) Peripheral nerve damage associated with administration of taxanes in patients with cancer. Crit. Rev. Oncol. Hematol., 66, 218-88.
15. Asano, N. (2003) Glycosidase inhibitors: update and perspectives on clinical use. Glycobiology, 13, 93R-104R.
16. Ashley, E.A., Lwin, K.M., McGready, R., Simon, W.H., Phaiphun, L., Proux, S., Wangseang, N., Taylor, W., Stepniewska, K., Nawamaneerat, W., Thwai, K.L., Barends, M., Leowattana, W., Olliaro, P., Singhasivanon, P., White, N.J. and Nosten, F. (2006) An open label randomized comparison of mefloquine-artesunate as separate tablets versus a new co-formulated combination for the treatment of uncomplicated multidrug-resitent falciparium malaria in Thailand. Trop. Med. Int. Health, 11, 1653-60.
17. Augustin, M., Bock, P.R., Hanisch, J., Karasmann, M. and Schneider, B. (2005) Safety and efficacy of the long-term adjuvant treatment of primary intermediate-to highrisk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung, 55, 38-49.
18. Balasubramanian, S. and Eckert, R. (2007) Curcumin suppresses AP1 transcription factor-dependent differentiation and activates apoptosis in human epidermal keratinocytes. J. Biol. Chem., 282, 6707-15.
19. Banerjee, S., Li, Y., Wang, Z. and Sarkar, F.H. (2008) Multi-targeted therapy of cancer by genistein. Cancer Lett., 269, 226-42.
20. Banerjee, S., Panda, C.K. and Das, S. (2006) Clove (Syzygium aromaticum L.), a potential chemopreventive agent for lung cancer. Carcinogenesis, 27, 1645-54.
21. Beretta, G.L. and Zunino, F. (2007) Relevance of extracellular and intracellular interactions of camptothecins as determinants of antitumor activity Biochem. Pharmacol., 74, 1437-44.
22. Berg, J.M., Tymoczko, J.L. and Stryer, L. (2002) Biochemistry, 5th edn, W.H. Freemann, New York.
23. Bertagnolli, M.M. (2007) Chemoprevention of colorectal cancer with cyclooxygenase-2 inhibitors: two steps forward, one step back. Lancet Oncol., 8, 439-43.
24. Beutler, J.A., Cardelina II, J.H., McMahon, J.B., Shoemaker, R.H. and Boyd, M.R. (1995) Antiviral and antitumor metabolites, in Phytochemistry of Medicinal Plants (eds. J.T. Amason, R. Mata and J.T. Romeo), Plenum Press, New York and London, pp. 47-64.
25. Bible, K.C. and Kaufmann, S.H. (1996) Flavopiridol: a cytotoxic flavone that induces cell death in noncycling A549 human lung carcinoma cells. Cancer Res., 56, 4856-61.
26. Bible, K.C. and Kaufmann, S.H. (1997) Cytotoxic synergy between flavopiridol (NSC 649890, L86-8275) and various antineoplastic agents: the importance of sequence of administration. Cancer Res., 57, 3375-80.
27. Bock, P.R., Friedel, W.E., Hanisch, J., Karasmann, M. and Schneider, B. (2004) Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results of a multi-center, comparative, epidemiological cohort study in Germany and Switzerland. Arzneimittelforschung, 54, 456-66.
28. Braun, J.M., Gemmell, C.G., Beuth, J., Ko, H.L. and Pulverer, G. (1995) Respiratory burst of human polymorphonuclear leukocytes in response to the galactosidespecific mistletoe lectin. Int. J. Med. Microbiol. Virol. Parasitol. Infect. Dis., 283, 90-94.
29. Büchele, B., Zugmaier, W., Estrada, A., Genze, F., Syrovets, T., Paetz, C., Schneider, B. and Simmet, T. (2006) Characterization of 3α-acetyl-11-keto-α-boswellic acid, a pentacyclic triterpenoid inducing apoptosis in vitro and in vivo. Planta Med., 72, 1285-9.
30. Büssing, A., Kochskämper, H., Rieger, S., Schierholz, J.M., Schlodder, D. and Schietzel, M. (2008) In vitro response of stimulated B-CLL lymphocytes of patients treated with Viscum album L. extracts. Anticancer Res., 27, 4195-200.
31. Butler, M.S. (2005) Natural products to drugs: natural product derived compounds in clinical trials. Nat. Prod. Rep., 22, 162-95.
32. Butterweck, V., Böckers, T., Korte, B., Wittkowski, W. and Winterhoff, H. (2002a) Long-term effects of St. John's wort and hypericin on monoamine levels in rat hypothalamus and hippocampus. Brain Res., 930, 21-9.
33. Butterweck, V., Hegger, M. and Winterhoff, H. (2008) Flavonoids of St. John's wort reduce HPA axis function in the rat. Planta Med., 70, 1008-11.
34. Butterweck, V., Nahrstedt, A., Evans, J., Hufeisen, S., Rauser, L., Savage, J., Popadak, B., Ernsberger, P. and Roth, B.L. (2002b) In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. Psychopharmacology, 162, 193-202.
35. Butterweck, V., Petereit, F., Winterhoff, H. and Nahrstedt, A. (1998) Solubilized hypericin and pseudohypericin from Hypericum perforatum exert antidepressant activity in the forced swimming test. Planta Med., 64, 291-4.
36. Butterweck, V., Winterhoff, H. and Herkenham, M. (2001) St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats. Mol. Psychiatry, 6, 547-64.
37. Carlson, B.A., Dubay, M.M., Sausville, E.A., Brizuela, L. and Worland, P.J. (1996) Flavopiridol induces G, arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Cancer Res., 56, 2973-6.
38. Cebovic, T., Spasic, S. and Popvic, M. (2008) Cytotoxic effects of the Viscum album L. extract on Ehrlich tumour cells in vivo. Phytother. Res., 22, 1097-103.
39. Chaplin, D.J., Horsman, M.R. and Siemann, D.W. (2006) Current development status of small-molecule vascular disrupting agents. Curr. Opin. Investig. Drugs, 7, 522-8.
40. Chatterjee, S.S., Bhattacharya, S.K., Wonnemann, M., Singer, A. and Müller, W.E. (1998) Hyperforin as a possible antidepressant component of Hypericum extracts. Life Sci., 63, 499-510.
41. Choi, S.H., Lyu, S.Y. and Park, W.B. (2004) Mistletoe lectin induces apoptosis and telomerase inhibition in human A253 cancer cells through dephosphorylation of Akt. Arch. Pharm. Res., 27, 68-76.
42. Chrzan, B.G. and Bradford, P.G. (2007) Phytoestrogens activate estrogen receptor beta1 and estrogenic responses in human breast and bone cancer cell lines. Mol. Nutr. Food Res., 51, 171-7.
43. Chu, Q., Vincent, M., Logan, D., Mackay, J.A. and Evans, W.K. (2005) Taxanes as first-line therapy for advanced non-small cell lung cancer: a systematic review and practice guideline. Lung Cancer, 50, 355-74.
44. Cirla, A. and Mann, J. (2003) Combretastatins: from natural products to drug discovery. Nat. Prod. Rep., 20, 558-64.
45. Colgate, E.C., Miranda, C.L., Stevens, J.F., Bray, T.M. and Ho, E. (2007) Xanthohumol, a prenylflavonoid derived from hops induces apoptosis and inhibits NF-kappaB activation in prostate epithelial cells. Cancer Lett., 246, 201-9.
46. Covello, P.S. (2008) Making artemisinin. Phytochemistry, 69, 2881-5.
47. Croom, E.M., Jr. (1995) Taxus for taxol and taxoids, in Taxol® Science and Applications (ed. M. Suffness), CRC Press, Boca Raton, New York, London, Tokyo, pp. 37-70.
48. Cuaz-Pérolin, C., Billiet, L., Baugé, E., Copin, C., Scott-Algara, D., Genze, F., Büchele, B., Syrovets, T., Simmet, T. and Rouis, M. (2008) Antiinflammatory and antiatherogenic effects of the NF-ΚB inhibitor acetyl-11-keto-α-boswellic acid in LPSchallenged ApoE-/-mice. Arterioscler. Thromb. Vasc. Biol., 28, 272-7.
49. Curini, M., Cravotto, G., Epifano, F. and Giannone, G. (2006) Chemistry and biological activity of natural and synthetic prenyloxycoumarins. Curr. Med. Chem., 13, 199-222.
50. De Clercq, E. (2000) Current lead natural products for the chemotherapy of human immunodeficiency virus (HIV) infection. Med. Res. Rev., 20, 323-49.
51. DeKosky, S.T., Williamson, J.D., Fitzpatrick, A.L., Kronmal, R.A., Ives, D.G., Saxton, J.A., Lopez, O.L., Burke, G., Carlson, M.C., Fried, L.P., Kuller, L.H., Robbins, J.A., Tracy, R.P., Woolard, N.F., Dunn, L., Snitz, B.E., Nahin, R.L. and Furberg, C.D. (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300, 2253-62.
52. Del Pilar Crespo, M., Avery, T.D., Hanssen, E., Fox, E., Robinson, T.V., Valente, P., Taylor, D.K. and Tilley, L. (2008) Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology. Antimicrob. Agents Chemother., 52, 98-109.
53. Delmulle, L., Bellahcene, A., Dhooge, W., Comhaire, F., Roelens, F., Huvaere, K., Heyerick, A., Castronovo, V. and De Keukeleire, D. (2006) Anti-proliferative properties of prenylated flavonoids from hops (Humulus lupulus L.) in human prostate cancer cell lines. Phytomedicine, 13, 732-4.
54. Di, Y.M., Li, C.G., Xue, C.C. and Zhou, S.F. (2008) Clinical drugs that interact with St. John's wort and implication in drug development. Curr. Pharm. Des., 14, 1723-42.
55. Dietz, B.M., Kang, Y.H., Liu, G., Eggler, A.L., Yao, P., Chadwick, L.R., Pauli, G.F., Farnsworth, N.R., Mesecar, A.D., van Breemen, R.B. and Bolton, J.L. (2005) Xanthohumol isolated from Humulus lupulus inhibits menadione induced DNA damage through induction of quinine reductase. Chem. Res. Toxicol., 18, 1296-305.
56. Donovan, D. and Vahdat, L.T. (2008) Epothilones: clinical update and future directions. Oncology, 22, 408-16.
57. Drees, M., Dengler, W.A., Roth, T., Labonte, H., Mayo, J., Malspeis, L., Grever, M., Sausville, E.A. and Fiebig, H.H. (1997) Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. Clin. Cancer Res., 3, 273-9.
58. Eckstein-Ludwig, U., Webb, R.J., van Goethem, I.D., East, J.M., Lee, A.G., Kimura, M., O'Neill, P.M., Bray, P.G., Ward, S.A. and Krishna, S. (2003) Artemisinins target the SERCA of Plasmodium falciparum. Nature, 424, 957-61.
59. Einzig, A.I., Wiernik, P.H., Sasloff, J., Runowicz, C.D. and Goldberg, G.L. (1992) Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian cancer. J. Clin. Oncol., 10, 1748-53.
60. Elluru, S., van Huyen, J.P., Delignat, S., Prost, F., Bayry, J., Kazatchkine, M.D. and Kaveri, S.D. (2006) Molecular mechanisms underlying the immunomodulatory effects of mistletoe (Viscum album L.) extracts Iscador. Arzneimittelforschung, 56, 461-6.
61. Endo, Y., Tsurugi, K. and Franz, H. (1988) The site of action of the A-chain ofmistletoe lectin I on eukaryotic ribosomes: the RNA N-glycosidase activity of the protein. FEBS Lett., 231, 378-80.
62. Ernst (2008) Frankincense: systematic review. BMJ, 337, a2813.
63. Etiévant, C., Kruczynski, A., Barret, J.M., Perrin, D., van Hille, B., Guminski, Y. and Hill, B.T. (2000) F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother. Pharmacol., 46, 101-11.
64. Etzel, R. (1996) Special extract of Boswellia serrata (H 15) in the treatment of rheumatoid arthritis. Phytomedicine, 3, 91-4.
65. Extra, J.-M., Rousseau, F., Bruno, R., Clavel, M., Le Bail, N. and Marty, M. (1993) Phase I and pharmacokinetic study of taxotere (RP 56976; NSC 628503) given as short intravenous infusion. Cancer Res., 53, 1037-42.
66. Fornier, M.N., Rathkopf, D., Shah, M., Patil, S., O'Reilly, E., Tse, A.N., Hudis, C., Lefkowitz, R., Kelsen, D.P. and Schwartz, G.K. (2007) Phase I dose-finding study of weekly docetaxel followed by flavopiridol for patients with advanced solid tumors. Clin Cancer Res., 13, 5841-6.
67. Franz, H. (1986) Mistletoe lectins and their A and B chains. Oncology, 43, 23-34.
68. Fumoleau, P. (1997) Efficacy and safety of docetaxel in clinical trials. Am. J. Health Syst. Pharm., 54, S19-24.
69. Gabr, A., Kuin, A., Aalders, M., El-Gawly, H. and Smets, L.A. (1997) Cellular pharmacokinetics and cytotoxicity of camptothecin and topotecan at normal and acidic pH. Cancer Res., 57, 4811-6.
70. Galletti, E., Magnani, M., Renzulli, M.L. and Botta, M. (2007) Paclitaxel and docetaxel resistance: molecular mechanisms and development of new generation taxanes. ChemMedChem., 2, 920-42.
71. Garcia-Carbonero, R. and Supko, J.G. (2002) Current perspectives on the clinical experience, pharmacology and continued development of the camptothecins. Clin. Cancer Res., 8, 641-61.
72. Gastpar, M., Singer, A. and Zeller, K. (2005) Efficacy and tolerability of hypericum extract STW3 in long-term treatment with a once daily dosage in comparison with sertaline. Pharmacopsychiatry, 38, 78-86.
73. Gerhäuser, C., Alt, A., Heiss, E., Gamal-Elden, A., Klimo, K., Knauft, J., Neumann, I., Scherf, H.-R., Frank, N., Bartsch, H. and Becker, H. (2002) Cancer chemopreventive activity of xanthohumol a natural product derived from hop. Mol. Cancer Ther., 1, 959-69.
74. German, P.I. and Aweeka, F.T. (2008) Clinical pharmacology of artemisinin-based combination therapies. Clin. Pharmacokinet., 47, 91-102.
75. Giovanella, B.C., Hinz, H.R., Kozielski, A.J., Stehlin, J.S., Silber, R. and Potmesil, M. (1991) Complete growth inhibition of human cancer xenografts in nude mice by treatment with 20(S)-camptothecin. Cancer Res., 51, 3052-5.
76. Gligorov, J. and Lotz, J.P. (2004) Preclinical pharmacology of the taxanes: implications of the differences. Oncologist, 9(Suppl 2), 3-8.
77. Gomes, A., Fernandes, E., Lima, J.L., Mira, L. and Corvo, M.L. (2008) Molecularmechanisms of anti-inflammatory activity mediated by flavonoids. Curr. Med. Chem., 15, 1586-605.
78. Gottlieb, J.A. and Luce, J.K. (1972) Treatment of malignant melanoma with camptothecin (NSC-100880). Cancer Chemother. Rep., 56, 103-5.
79. Guéritte-Voegelein, F., Guénard, D., Lavelle, F., LeGoff, M.-T., Mangatal, L. and Potier, P. (1991) Relationships between the structure of taxol analogues and their antimitotic activity. J. Med. Chem., 34, 992-8.
80. Gupta, O.P., Sharma, N. and Chand, D. (1992) A sensitive and relevant model for evaluating anti-inflammatory activity, papaya latex-induced rat paw inflammation. J. Pharmacol. Toxicol. Methods, 28, 15-9.
81. Harborne, J.B. (ed.) (1994) The Flavonoids: Advances in Research Since 1986. Chapman & Hall, London.
82. Hartmann, J.T. and Lipp, H.P. (2006) Camptothecin and podophyllotoxin derivatives:inhibitors of topoisomerase I and II-mechanisms of action, pharmacokinetics and toxicity profile. Drug Saf., 29, 209-30.
83. Hatcher, H., Planalp, R., Cho, J., Torti, F.M. and Torti, S.V. (2008) Curcumin: from ancient medicine to current clinical trials. Cell Mol. Life Sci., 65, 1631-52.
84. Haynes, R.K., Chan, W.C., Lung, C.M., Uhlemann, A.C., Eckstein, U., Taramelli, D., Parapini, S., Monti, D. and Krishna, S. (2007) The Fe2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins:the unlikelihood of C-centered radicals as bioactive intermediates. ChemMedChem, 2, 1480-97.
85. Heiny, B.M., Albrecht, V. and Beuth, J. (1998) Correlation of immune cell activities and betaendorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract. Anticancer Res., 18, 583-6.
86. Hinnen, P. and Eskens, F.A.L.M. (2007) Vascular disrupting agents in clinical development. Br. J. Cancer, 96, 1159-65.
87. Holmes, F.A., Walters, R.S., Theriault, R.L., Forman, A.D., Newton, L.K., Raber, M.N., Buzdar, A.U., Frye, D.K. and Hortobagyi, G.N. (1991) Phase II trial of taxol: an active drug in the treatment of metastatic breast cancer. J. Natl. Cancer Inst., 83, 1797-805.
88. Holz-Smith, S.L., Sun, I.C., Jin, L., Matthews, T.J., Lee, K.H. and Chen, C.H. (2001) Role of human immunodeficiency virus (HIV) type 1 envelope in the anti-HIV activity of the betulinic acid derivative IC9564. Antimicrob. Agents Chemother., 45, 60-66.
89. Horsch, S. and Walther, C. (2004) Ginkgo biloba special extract EGb 761 in the treatment of peripheral arterial occlusive disease (PAOD)-a review based on randomized, controlled studies. Int. J. Clin. Pharmacol. Ther., 42, 63-72.
90. Hostanska, K., Daum, G. and Saller, R. (2002) Cytostatic and apoptosis inducing activity of boswellic acids toward malignant cell lines in vitro. Anticancer Res., 22, 2853-62.
91. Hsiang, Y.H., Hertzberg, R., Hecht, S. and Liu, L. (1985) Camptothecin induces proteinlinked DNA breaks via mammalian DNA topoisomerase I. J. Biol. Chem., 260, 14873-8.
92. Hsiang, Y.H., Liu, L.F., Wall, M.E., Wani, M.C., Kirschenbaum, S., Silber, R. and Potmesil, M. (1989) DNAtopoisomerase I-mediatedDNAcleavage and cytotoxicity of camptothecin analogs. Cancer Res., 49, 4385-9.
93. Huang, L., Ho, P., Lee, K.H. and Chen, C.H. (2006) Synthesis and anti-HIV activity of bi-functional betulinic acid derivatives. Bioorg Med Chem., 14, 2279-89.
94. Huang, M.T., Newmark, H.L. and Frenkel, K. (1997) Inhibitory effects of curcumin on tumorgenesis in mice. J. Cell Biochem., 27, 26-34.
95. Hutagalung, R., Paiphun, L., Ashley, E.A., McGready, R., Brockman, A., Thwai, K.L., Singhasivanon, P., Jelinek, T., White, N.J. and Nosten, F.H. (2005) A randomized trial of artemether-lumefantrine versus mefloquine-artesunate for the treatment of uncomplicated multi-drug resistant Plasmodium falciparum on the western border of Thailand. Malar. J., 4, 46.
96. Industrial Forum (2002) Taxol® : gewinnung aus Pflanzenzellkulturen-Zytostatikum jetzt biotechnologisch hergestellt. Information by Bristol-Myers Squibb. Onkologie, 25, 484-7.
97. Janakiram, N.B., Indranie, C., Malisetty, S.V., Jagan, P., Steele, V.E. and Rao, C.V. (2008) Chemoprevention of colon carcinogenesis by oleanolic acid and its analog in male F344 rats and modulation of COX-2 and apoptosis in human colon HT-29 cancer cells. Pharm. Res., 25, 2151-7.
98. Jaxel, C., Kohn, K.W., Wani, M.C., Wall, M.E. and Pommier, Y. (1989) Structure-activity study of the actions of camptothecin derivatives on mammalian topoisomerase I:evidence for a specific receptor site and for a relation to antitumor activity. Cancer Res., 49, 1465-9.
99. Kamchonwongpaisan, S., McKeever, P., Hossler, P., Ziffer, H. and Meshnick, S.R. (1997) Artemisinin neurotoxicity: neuropathology in rats and mechanistic studies in vitro. Am. J. Trop. Med. Hyg., 56, 7-12.
100. Kandaswami, C., Lee, L.T., Lee, P.P., Hwang, J.J., Ke, F.C., Huang, Y.T. and Lee, M.T. (2005) The antitumor activities of flavonoids. In Vivo, 19, 895-909.
101. Karp, J.E., Smith, B.D., Levis, M.J., Gore, S.D., Greer, J., Hattenburg, C., Briel, J., Jones, R.J., Wright, J.J. and Colevas, A.D. (2007) Sequential flavopiridol, cytosine arabinoside, and mitoxantrone: a phase II trial in adults with poor-risk acute myelogenous leukemia. Clin. Cancer Res., 13, 4467-73.
102. Katsumata, N. (2003) Docetaxel: an alternative taxane in ovarian cancer. Br. J. Cancer, 89(Suppl. 3), S9-15.
103. Kelloff, G.J., Boone, C.W., Crowell, J.A., Steele, V.E., Lubet, R.A., Doody, L.A., Malone, W.F., Hawk, E.T. and Sigman, C.C. (1996a) New agents for cancer chemoprevention. J. Cell Biochem., 26, 1-28.
104. Kelloff, G.J., Crowell, J.A., Hawk, E.T., Steele, V.E., Lubet, R.A., Boone, C.W., Covey, J.M., Doody, L.A., Omenn, G.S., Greenwald, P., Hong, W.K., Parkinson, D.R., Bargheri, D., Baxter, G.T., Blunden, M., Doeltz, M.K., Eisenhauer, K.M., Johnson, K., Knapp, G.G., Longfellow, D.G., Malone, W.F., Nayfield, S.G., Seifried, H.E., Swall, L.M. and Sigman, C.C. (1996b) Strategy and planning for chemopreventive drug development: clinical Development Plans II. J. Cell. Biochem., 26, 54-71.
105. Khan, N., Afaq, F. and Mukhtar, H. (2008) Cancer chemoprevention through dietary antioxidants: progress and promise. Antioxid. Redox Signal., 10, 475-510.
106. Kimmatkar, N., Thawani, V., Hingorani, L. and Khiyani, R. (2003) Efficacy and tolerability of Boswellia serrata extract in treatment of osteoarthritis of knee-a randomized double blind placebo controlled trial. Phytomedicine, 10, 3-7.
107. Kindermans, J.M., Pilloy, J., Olliaro, P. and Gomes, M. (2007) Ensuring sustained ACT production and reliable artemisinin supply. Malar. J., 6, 15.
108. Kluza, J., Mazinghien, R., Irwin, H., Hartley, J.A. and Bailly, C. (2006) Relationships betweenDNAstrand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide. Anticancer Drugs, 17, 155-64.
109. Kostelac, D., Rechkemmer, G. and Briviba, K. (2003) Phytoestrogensmodulate binding response of estrogen receptors alpha and beta to the estrogen response element. J. Agric. Food Chem., 51, 7632-5.
110. Kumaraguruparan, R., Seshagiri, P.B., Hara, Y. and Nagini, S. (2007) Chemoprevention of ratmammary carcinogenesis by black tea polyphenols:modulation of xenobioticmetabolizing enzymes, oxidative stress, cell proliferation, apoptosis, and angiogenesis. Mol. Carcinog., 46, 797-806.
111. Kunnumakkara, A.B., Anand, B. and Aggarwal, B.B. (2008) Curcumin inhibits proliferation, invasion, angiogenesis and metastasis of different cancers through interaction with multiple cell signaling proteins. Cancer Lett., 269, 199-225.
112. Kwon, K.H., Barve, A., Yu, S., Huang, M.T. and Kong, A.N. (2007) Cancer chemoprevention by phytochemicals: potential molecular targets, biomarkers and animal models. Acta Pharmacol. Sin., 28, 1409-21.
113. Lamy, V., Roussi, S., Chaabi, M., Gossé, F., Schall, N., Lobstein, A. and Raul, F. (2007) Chemopreventive effects of lupulone, a hop β-acid, on human colon cancer-derived metastatic SW620 cells and in a rat model of colon carcinogenesis. Carcinogenesis, 28, 1575-81.
114. Legarza, K. and Yang, L.X. (2005) Novel camptothecin derivatives. In Vivo, 19, 282-92.
115. Li, F., Goila-Gaur, R., Salzwedel, K., Kilgore, N.R., Reddick, M., Matallana, C., Castillo, A., Zoumplis, D., Martin, D.E., Orenstein, J.M., Allaway, G.P., Freed, E.O. and Wild, C.T. (2003) PA-457: a potent HIV inhibitor that disrupts core condensation by targeting a late step in Gag processing. Proc. Natl. Acad. Sci. USA, 100, 13555-60.
116. Liew, S.T. and Yang, L.X. (2008) Design, synthesis and development of novel camptothecin drugs. Curr. Pharm. Des., 14, 1078-97.
117. Lin, J.K., Chen, Y.C., Huang, Y.T. and LinShiau, S.Y. (1997) Suppression of protein kinase C and nuclear oncogene expression as possible molecular mechanisms of cancer chemoprevention by apigenin and curcumin. J. Cell. Biochem., 28-29, 39-48.
118. Liu, J.J., Nilsson, A., Oredsson, S., Badmaev, V., Zhao, W.Z. and Duan, R.D. (2002) Boswellic acids trigger apoptosis via a pathway dependent on caspase-8 activation but independent on Fas/Fas ligand interaction in colon cancer HT-29 cells. Carcinogenesis, 23, 2087-93.
119. Liu, L.F. (1989) DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem., 58, 351-75.
120. Liu, L.F., Desai, S.D., Li, T.K., Mao, Y., Sun, M. and Sim, S.P. (2000) Mechanism of action of camptothecin. Ann. N. Y. Acad. Sci., 922, 1-10.
121. Losiewicz, M.D., Carlson, B.A., Kaur, G., Sausville, E.A. and Worland, P.J. (1994) Potent inhibition of cdc2 kinase activity by the flavonoid, L86-8275. Biochem. Biophys. Res. Commun., 201, 589-95.
122. Lu, H., Li, J., Zhang, D., Stoner, G.D. and Huang, C. (2006) Molecular mechanisms involved in chemoprevention of black raspberry extracts: fromtranscription factors to their target genes. Nutr. Cancer, 54, 69-78.
123. Lyu, S.Y. and Park, W.B. (2007) Effects of Korean mistletoe lectin (Viscum album coloratum) on proliferation and cytokine expression in human peripheral blood mononuclear cells and T-lymphocytes. Arch. Pharm. Res., 30, 1252-64.
124. Madisch, A., Miehlke, S., Eichele, O., Mrwa, J., Bethke, B., Kuhlisch, E., Bästlein, E., Wilhelms, G., Morgner, A., Wigginghaus, B. and Stolte, M. (2007) Boswellia serrata extract for the treatment of collagenous colitis. A double blind, randomized, placebo-controlled, multicenter trial. Int. J. Colorectal Dis., 22, 1445-51.
125. Mannel, M. (2004) Drug interactions with St. John's wort: mechanisms and clinical implications. Drug Saf., 27, 773-97.
126. Markman, M. (2008) Antineoplastic agents in the management of ovarian cancer:current status and emerging therapeutic strategies. Trends Pharmacol. Sci., 29, 515-9.
127. Matthews, C.P., Colburn, N.H. and Young, M.R. (2007) AP-1 a target for cancer prevention. Curr. Cancer Drug Targets, 7, 317-24.
128. Mayer, F., Müller, S., Malenke, E., Kuczyk, M., Hartmann, J.T. and Bokemeyer, C. (2005) Induction of apoptosis by flavopiridol unrelated to cell cycle arrest in germ cell tumour derived cell lines. Invest. New Drugs, 23, 205-11.
129. McGuire, W.P., Rowinsky, E.K., Rosenshein, N.B., Grumbine, F.C., Ettinger, D.S., Àmstrong, D.K. and Donehower, R.C. (1989) Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med., 111, 273-9.
130. Meshnick, S.R. (2002) Artemisinin: mechanisms of action, resistance and toxicity. Int. J. Parasitol., 32, 1655-60.
131. Meshnick, S.R., Taylor, T.E. and Kamchonwongpaisan, S. (1996) Artemisinin and the antimalarial endoperoxides: from herbal remedy to targeted chemotherapy. Microbiol. Rev., 60, 301-15.
132. Miranda, C.L., Stevens, J.F., Helmrich, A., Henderson, M.C., Rodriguez, R.J., Yang, Y.H., Deinzer, M.L., Barnes, D.W. and Buhler, D.R. (1999) Antiproliferative and cytotoxic effects of prenylated flavonoids from hops (Humulus lupulus) in human cancer cell lines. Chem. Toxicol., 37, 271-85.
133. Miranda, C.L., Yang, Y.H., Henderson, M.C., Stevens, J.F., Santana-Rios, G., Deinzer, M.L. and Buhler, D.R. (2000) Prenylflavonoids from hops inhibit the metabolic activation of the carcinogenic heterocyclic amine 2-amino-3-methylimidazo[4, 5-f]quinoline, mediated by cDNA-expressed human CYP1A2. Drug Metab. Dispos., 28, 1297-302.
134. Moertel, C.G., Schutt, A.J., Reitemerer, R.G. and Hahn, R.G. (1972) Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother. Rep., 56, 95-101.
135. Monteiro, R., Calhau, C., Silva, A.O., Pinheiro-Silva, S., Guerreiro, S., Gärtner, F., Azevedo, I. and Soares, R. (2008) Xanthohumol inhibits inflammatory factor production and angiogenesis in breast cancer xenografts. J. Cell. Biochem., 104, 1699-707.
136. Monteiro, R., Faria, A., Azevedo, I. and Calhau, C. (2007) Modulation of breast cancer cell survival by aromatase inhibiting hop (Humulus lupulus L.) flavonoids. J. Steroid Biochem. Mol. Biol., 105, 124-30.
137. Montero, A., Fosella, F., Hortobagyi, G. and Valero, V. (2005) Docetaxel for treatment of solid tumours: a systematic review of clinical data. Lancet Oncol., 6, 229-39.
138. Moon, Y.J., Wang, X. and Morris, M.E. (2006) Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. In vitro, 20, 187-210.
139. Motwani, M., Jung, C., Sirotnak, F.M., She, Y., Shah, M.A., Gonen, M. and Schwartz, G.K. (2001) Augmentation of apoptosis and tumor regression by flavopiridol in the presence of CPT-11 in Hct116 colon cancermonolayers and xenografts. Clin. Cancer Res., 7, 4209-19.
140. Muggia, F.M., Creaven, P.J., Hanson, H.H., Cohen, M.C. and Selawry, O.S. (1972) Phase I clinical trial ofweekly and daily treatment with camptothecin (NSC-100880):correlation with preclinical studies. Biochemistry, 56, 515-21.
141. Müller, W.E., Singer, A. and Wonnemann, M. (2001) Hyperforin-antidepressant activity by a novel mechanism of action. Pharmacopsychiatry, 34(Suppl. 1), S98-102.
142. Naik, R.G., Kattige, S.L., Bhat, S.V., Alreja, B., de Souza, N.J. and Rupp, R.H. (1988) An anti-inflammatory cum immunomodulatory piperidinylbenzopyranone from Dysoxylum binectariferum: isolation, structure and total synthesis. Tetrahedron, 44, 2081-6.
143. Nakamura, Y., Ohto, Y., Murakami, A., Osawa, T. and Ohigashi, H. (1998) Inhibitory effects of curcumin and tetrahydrocurcuminoids on the tumor promotor-induced reactive oxygen species generation in leukocytes in vitro and in vivo. Jpn. J. Cancer Res., 89, 361-70.
144. Newmann, D.J. and Cragg, G.M. (2007) Natural products as sources of new drugs over the last 25 years. J. Nat. Prod., 70, 461-77.
145. Nosten, F. and White, N.J. (2007) Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg., 77, 181-92.
146. O'Reilly, E.M. and Ilson, D.H. (2001) Cisplatin and irinotecan in upper gastrointestinal malignancies. Oncology, 15 (3 Suppl 5), 42-5.
147. Oberpichler-Schwenk, H. and Krieglstein, J. (1992) PharmakologischeWirkungen von Ginkgo biloba-Extrakt and-Inhaltsstoffen. Pharm. Unserer Zeit, 21, 224-35.
148. Pendurthi, U.R., Williams, J.T. and Rao, L.V. (1997) Inhibition of tissue factor gene activation in cultured endothelial cells by curcumin: suppression of activation of transcription factors, Egr-1, AP-1 and NF-kappa B. Arterioscler. Thromb. Vasc. Biol., 17, 3406-13.
149. Pöckel, D., Tausch, L., Kather, N., Jauch, J. and Werz, O. (2006) Boswellic acids stimulate arachidonic acid release and 12-lipoxygenase activity in human platelets independent of Ca2+ and differentially interact with platelet-type 12-lipoxygenase. Mol. Pharmacol., 70, 1071-8.
150. Pöckel, D. and Werz, O. (2006) Boswellic acids: biological actions and molecular targets. Curr. Med. Chem., 13, 3359-69.
151. Pommier, Y. (1996) Eukaryotic DNA topoisomerase I: genome gatekeeper and its intruders, camptothecins. Semin. Oncol., 23, 3-10.
152. Pommier, Y. and Kohn, K.W. (1989) Topoisomerase II inhibition by antitumor intercalators and demethylepipodophyllotoxins, in Developments in Cancer Chemotherapy (ed. R.I. Glazer), CRC Press, Boca Raton, pp. 175-96.
153. Posner, G.H., Chang, W., Hess, L., Woodard, L., Sinishtaj, S., Usera, A.R., Maio, W., Rosenthal, A.S., Kalinda, A.S., D'Angelo, J.G., Petersen, K.S., Stohler, R., Chollet, J., Santo-Tomas, J., Snyder, C., Rottmann, M., Wittlin, S., Brun, R. and Shapiro, T.A. (2008) Malaria infected mice are cured by oral administration of new artemisinin derivatives. J. Med. Chem., 51, 1035-42.
154. Posner, G.H., Oh, C.H., Wang, D., Gerena, L., Milhous, W.K. and Asawamahasadka, W. (1994) Mechanism-based design, synthesis, and in vitro antimalarial testing of new 4-methylated trioxanes structurally related to artemisinin: the importance of a carbon-centered radical for antimalarial activity. J. Med. Chem., 37, 1256-8.
155. Potterat, O. and Hamburger, M. (2008) Drug Discovery and development with plantderived compounds. Prog. Drug Res., 65, 47-118.
156. Ramos, S. (2007) Effects of dietary flavonoids on apoptotic pathways related to cancer chemoprevention. J. Nutr. Biochem., 18, 427-42.
157. Ramos, S. (2008) Cancer chemoprevention and chemotherapy: dietary polyphenols and signalling pathways. Mol. Nutr. Food Res., 52, 507-26.
158. Rasheed, Z.A. and Rubin, E.H. (2003) Mechanisms of resistance to topoisomerase I-targeting drugs. Oncogene, 22, 7296-304.
159. Ravindranath, M.H., Muthugounder, S., Presser, N. and Viswanathan, S. (2004) Anticancer therapeutic potential of soy isoflavone, genistein. Adv. Exp. Med. Biol., 546, 121-65.
160. Raynal, N.J., Momparler, L., Charbonneau, M. and Momparler, R.L. (2008) Antileukemic activity of genistein, a major isoflavone present in soy products. J. Nat. Prod., 71, 3-7.
161. Reddy, S. and Aggarwal, B.B. (1994) Curcumin is a noncompetitive and selective inhibitor of phosphorylase kinase. FEBS Lett., 341, 19-22.
162. Ribereau-Gayon, G., Dumont, S., Müller, C., Jung, M.L., Poindron, P. and Anton, R. (1996) Mistletoe lectins I, II and III induce the production of cytokines by cultured human monocytes. Cancer Lett., 109, 33-8.
163. Rougier, P. and Bugat, R. (1996) CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Semin. Oncol., 23, 34-41.
164. Safayhi, H., Mack, T., Sabieraj, J., Anazodo, M.I., Subramanian, L.R. and Ammon, H.P.T. (1992) Boswellic acids: novel, specific, nonredox inhibitors of 5-lipoxygenase. J. Pharmacol. Exp. Ther., 261, 1143-6.
165. Safayhi, H., Rail, B., Sailer, E.R. and Ammon, H.P.T. (1997) Inhibition by Boswellic acids of human leukocyte elastase. J. Pharmacol. Exp. Ther., 281, 460-63.
166. Safayhi, H., Sailer, E.-R. and Ammon, H.P.T. (1995) Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-β-Boswellic acid. Mol. Pharmacol., 47, 1212-6.
167. Sailer, E.-R., Hörnlein, R.F., Subramanian, L.R., Ammon, H.P.T. and Safayhi, H. (1996a) Preparation of novel analogues of the nonredox-type noncompetitive leukotriene biosynthesis inhibitor, AKBA. Arch. Pharm., 329, 54-6.
168. Sailer, E.-R., Subramanian, L.R., Rall, B., Hörnlein, R.F., Ammon, H.P.T. and Safayhi, H. (1996b) Acetyl-11-keto-β-boswellic acid (AKBA): structure requirements for binding and 5-lipoxygenase inhibitory activity. Br. J. Pharmacol., 117, 615-8.
169. Saloustros, E. and Georgoulias, V. (2008) Docetaxel in the treatment of advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther., 8, 1207-22.
170. Saloustros, E., Mavroudis, D. and Georgoulias, V. (2008) Paclitaxel and docetaxel in the treatment of breast cancer. Expert Opin. Pharmacother., 9, 2603-16.
171. Sarkar, F.H., Adsule, S., Padhye, S., Kulkarni, S. and Li, Y. (2006) The role of genistein and synthetic derivatives of isoflavone in cancer prevention and therapy. Mini Rev. Med. Chem., 6, 401-7.
172. Schiff, P.B., Fant, J. and Horwitz, S.B. (1979) Promotion of microtubule assembly in vitro by taxol. Nature, 22, 665-7.
173. Schulz, V. (2002) Clinical trials with hypericum extracts in patients with depressionresults comparisons, conclusions for therapy with antidepressant drugs. Phytomedicine, 9, 468-74.
174. Schulz, V. (2006) Safety of St. John's Wort extract compared to synthetic antidepressants. Phytomedicine, 13, 199-204.
175. Schweizer, J. and Hautmann, C. (1999) Comparison of two dosages of Ginkgo biloba extract EGb 761 in patients with peripheral arterial occlusive disease Fontaine's stage IIb. A randomised, double-blind, multicentric clinical trial. Arzneimittelforschung, 49, 900-904.
176. Scripture, C.D., Figg, F.D. and Sparreboom, A. (2005) Paclitaxel chemotherapy: from empiricism to a mechanism-based formulation strategy. Ther. Clin. Risk Manag., 1, 107-14.
177. Sengupta, K., Alluri, K.V., Satish, A.R., Mishra, S., Golakoti, T., Sarma, K.V., Dey, D. and Raychaudhuri, S.P. (2008) A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res. Ther., 10, R85.
178. Shankar, S., Ganapathy, S., Chen, Q. and Srivastava, R. (2008) Curcumin sensitizes TRAIL-resistant xenografts: molecular mechanisms of apoptosis, metastasis and angiogenesis. Mol. Cancer, 7, 16.
179. Shankar, S. and Srivastava, R. (2007) Bax and Bak genes are essential for maximum apoptotic response by curcumin, a polyphenolic compound and cancer chemopreventive agent derived from turmeric, Curcuma longa. Carcinogenesis, 28, 1277-86.
180. Sharma, M.L., Bani, S. and Singh, G.B. (1989) Antiarthritic activity of boswellic acids in bovine serum albumin (BSA)-induced arthritis. Int. J. Immunopharmacol., 11, 647-52.
181. Shukla, S., Zaher, H., Hartz, A., Bauer, B., Ware, J.A. and Ambudkar, S.V. (2009) Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm. Res., 26, 480-87.
182. Siemoneit, U., Hofmann, B., Kather, N., Lamkemeyer, T., Madlung, J., Franke, L., Schneider, G., Jauch, J., Pöckel, D. and Werz, O. (2008) Identification and functional analysis of cyclooxygenase-1 as a molecular target of boswellic acids. Biochem. Pharmacol., 75, 503-13.
183. Singh, G.B. and Atal, C.K. (1986) Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new nonsteroidal anti-inflammatory agent. Agents Actions, 18, 407-12.
184. Singh, R., Sharma, M., Joshi, P. and Rawat, D.S. (2008) Clinical status of anti-cancer agents derived from marine sources. Anticancer Agents Med. Chem., 8, 603-17.
185. Smith, J.V. and Luo, Y. (2004) Studies onmolecular mechanisms of Ginkgo biloba extract. Appl. Microbiol. Biotechnol., 64, 465-72.
186. Smith, P.F., Ogundele, A., Forrest, A., Wilton, J., Salzwedel, K., Doto, J., Allaway, G.P. and Martin, D.E. (2007) Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-O-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob. Agents Chemother., 51, 3574-81.
187. Soler, M.H., Stoeva, S. and Voelter, W. (1998) Complete amino acid sequence of the B-chain of mistletoe lectin I. Biochem. Biophys. Res. Commun., 246, 596-601.
188. South, E.H., Exon, J.H. and Hendrix, K. (1997) Dietary curcumin enhances antibody response in rats. Immunopharmacol. Immunotoxicol., 19, 105-19.
189. Sreejayan, N. and Rao, M.N.A. (1997) Nitric oxide scavenging by curcuminoids. J. Pharm. Pharmacol. 49, 105-7.
190. Stein, G., Henn, W., von Lane, H. and Berg, P.I. (1998) Modulation of the cellular and humoral immune responses of tumor patients by mistletoe therapy. Eur. J. Med. Res., 3, 194-202.
191. Stein, G.M. and Berg, P.A. (1996) Evaluation of the stimulatory activity of a fermented mistletoe lectin-I free mistletoe extract on T-helper cells and monocytes in healthy individuals in vitro. Arzneim. Forsch. Drug Res., 46, 635-9.
192. Stoddart, C.A., Joshi, P., Sloan, B., Bare, J.C., Smith, P.C., Allaway, G.P., Wild, C.T. and Martin, D.E. (2007) Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PLoS One, 2, e1251.
193. Suffness, M. (ed.) (1995) Taxol® Science and Applications. CRC Press, Boca Raton, New York, London, Tokyo.
194. Suffness, M. and Wall, M.E. (1995) Discovery and development of taxol, in Taxol® Science and Applications (ed. M. Suffness), CRC Press, Boca Raton, New York, London, Tokyo, pp. 325.
195. Svejstrup, J.Q., Christiansen, K., Gromova, I.I., Andersen, A.H. and Westergaard, O. (1991) New techniques for uncoupling the cleavage and religation reactions of eukaryotic topoisomerase I: the mode of action of camptothecin at a specific recognition site. J. Mol. Biol., 222, 669-78.
196. Syed, D.N., Suh, Y., Afaq, F. and Mukhtar, H. (2008) Dietary agents for chemoprevention of prostate cancer. Cancer Lett., 265, 167-76.
197. Syrovets, T., Büchele, B., Krauss, C., Laumonnier, Y. and Simmet, T. (2005) Acetylboswellic acids inhibit lipopolysaccharide-mediated TNF-α induction inmonocytes by direct interaction with IΚB kinases. J. Immunol., 174, 498-506.
198. Ta, N. and Walle, T. (2007) Aromatase inhibition by bioavailable methylated flavones. J. Steroid Biochem. Mol. Biol., 107, 127-9.
199. Takada, Y., Sethi, G., Sung, B. and Aggarwal, B.B. (2008) Flavopiridol suppresses tumor necrosis factor-induced activation of activator protein-1, c-Jun N-terminal kinase, p38 mitogen-activated protein kinase (MAPK), p44/p42 MAPK, and Akt, inhibits expression of antiapoptotic gene products, and enhances apoptosis through cytochrome c release and caspase activation in human myeloid cells. Mol. Pharmacol., 73, 1549-57.
200. Teicher, B.A. (2008) Next generation of topoisomerase I inhibitors: rationale and biomarker strategies. Biochem. Pharmacol. 75, 1262-71.
201. Teicher, B.A., Holden, S.A., Khandakar, V. and Herman, T.S. (1993) Addition of a topoisomerase I inhibitor to trimodality therapy (cis-diamminediochloroplatinum(II)/heat/radiation) in a murine tumor. J. Cancer Res. Clin. Oncol., 119, 645-51.
202. Thangapazham, R.L., Sharma, A. and Maheshwari, R.K. (2006) Multiple molecular targets in cancer chemoprevention by curcumin. AAPS J., 8, E443-9.
203. Trigg, P.I. (1989) Quinghaosu (artemisinin) as an antimalarial drug, in Economic and Medicinal Plant Research (eds. H. Wagner, H. Hikino and N.R. Farnsworth), Academic Press, London, pp. 19-55.
204. Van Dongen, M., van Rossum, E., Kessels, A., Siedhorst, H. and Knipschild, P. (2003) Ginkgo for elderly people with dementia and age-associated memory impairment:a randomized clinical trial. J. Clin. Epidemiol., 56, 367-76.
205. Vennerstrom, J.L., Arbe-Barnes, S., Brun, R., Charman, S.A., Chiu, F.C., Chollet, J., Dong, Y., Dorn, A., Hunziker, D., Matile, H., McIntosh, K., Padmanilayam, M., Santo Tomas, J., Scheurer, C., Scorneaux, B., Tang, Y., Urwyler, H., Wittlin, S. and Charman, W.N. (2004) Identification of an antimalarial synthetic drug development candidate. Nature, 430, 900-904.
206. Vogel, S., Ohmayer, S., Brunner, G. and Heilmann, J. (2008) Natural and non-natural prenylated chalcones: synthesis, cytotoxicity and anti-oxidative activity. Bioorg. Med. Chem., 16, 4286-93.
207. Wall, M.E. and Wani, M.C. (1995) Camptothecin and taxol: discovery to clinic. Cancer Res., 55, 753-60.
208. Wall, M.E., Wani, M.C., Cook, C.E., Palmer, K.H., McPhail, A.T. and Sim, G.A. (1966) Plant antitumor agents. I. The isolation and structure of camptothecin: a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata. J. Am. Chem. Soc., 88, 3888-90.
209. Wani, M.C., Nicholas, A.W. and Wall, M.E. (1987) Plant antitumor agents. 28. Resolution of a key tricyclic synthon, 5' (RS)-1,5-dioxo-(5'-ethyl-5'-hydroxy-2'-H, 5'-H, 6'-H-6-oxopyrano) [3',4'-f]-6,8-tetrahydroindolizine: total synthesis and antitumor activity of 20(S)-and 20(R)-camptothecin. J. Med. Chem., 30, 2317-9.
210. Wani, M.C., Ronman, P.E., Lindley, J.T. and Wall, M.E. (1980) Plant tumor agents. 18. Synthesis and biological activity of camptothecin analogs. J. Med. Chem., 23, 554-60.
211. Wani, M.C., Taylor, H.L., Wall, M.E., Coggon, P. and McPhail, A.T. (1971) Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 93, 2325-7.
212. Wasserman, E., Sutherland, W. and Cvitkovic, E. (2001) Irinotecan plus oxaliplatin:a promising combination for advanced colorectal cancer. Clin. Colorectal Cancer, 3, 149-53.
213. White, E.L., Ross, L.J., Schmid, S.M., Kelloff, G.J., Steele, V.E. and Hill, D.L. (1998) Screening of potential cancer-preventing chemicals for inhibition of induction of ornithine decarboxylase in epithelial cells from rat trachea. Oncol. Rep., 5, 717-22.
214. Will-Shahab, L., Bauer, S., Kunter, U., Roots, I. and Brattström, A. (2008) St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive. Eur. J. Clin. Pharmacol., 65(3), 287-94.
215. Wirger, A., Perabo, F.G., Burgemeister, S., Haase, L., Schmidt, D.H., Döhn, C., Müller, S.C. and Jocham, D. (2005) Flavopiridol, an inhibitor of cyclin-dependent kinases, induces growth inhibition and apoptosis in bladder cancer cells in vitro and in vivo. Anticancer Res., 25, 4341-7.
216. Wonnemann, M., Singer, A., Siebert, B. and Mülller, W.E. (2001) Evaluation of synaptosomal uptake inhibition of most relevant constituents of St. John's wort. Pharmacopsychiatry, 34(Suppl. 1), S148-51.
217. Worland, P.J., Kaur, G. and Stetler-Stevenson, M. (1993) Alteration of the phosporylation state of p34 cdc2 kinase by the flavone, 186-8275, in breast carcinoma cells. Biochem. Pharmacol., 46, 1831-40.
218. Yang, C.S., Landau, J.M., Huang, M.T. and Newmark, H.L. (2001) Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu. Rev. Nutr., 21 381-406.
219. Yoon, T.J., Yoo, Y.C., Choi, O.B., Do, M.S., Kang, T.B., Lee, S.W., Azuma, I. and Kim, J.B. (1995) Inhibitory effect of Koreanmistletoe (Viscum album coloratum) extract on tumour angiogenesis and metastasis of haematogenous and non-haematogenous tumour cells in mice. Cancer Lett., 97, 83-91.
220. Yu, D., Sakurai, Y., Chen, C.H., Chang, F.R., Huang, L., Kashiwada, Y. and Lee, K.H. (2006) Anti-AIDS agents 69. Moronic acid and other triterpene derivatives as novel potent anti-HIV agents. J. Med. Chem., 49, 5462-9.
221. Yu, D., Wild, C.T., Martin, D.E., Morris-Natschke, S.L., Chen, C.H., Allaway, G.P. and Lee, K.H. (2005) The discovery of a class of novel HIV-1 maturation inhibitors and their potential in the therapy of HIV. Expert Opin. Investig. Drugs, 14, 681-93.